[1. C. A. Dendrou, L. Fugger and M. A. Friese, Immunopathology of multiple sclerosis, Nat. Rev. Immunol. 15 (2015) 545–558; https://doi.org/10.1038/nri387110.1038/nri3871]Search in Google Scholar
[2. A. Lugaresi, Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis, Expert Opin. Drug Metab. Toxicol.11 (2014) 295–306; https://doi.org/10.1517/17425255.2015.99331510.1517/17425255.2015.993315]Search in Google Scholar
[3. S. Weir, R. Torkin and H. R. Henney, Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis, Curr. Med. Res. Opin. 29 (2012) 1627–1636; https://doi.org/10.1185/03007995.2012.74922110.1185/03007995.2012.749221]Search in Google Scholar
[4. W. A. Coetzee, Y. Amarillo, J. Chiu, A. Chow, D. Lau, T. McCormack, H. Moreno, M. S. Nadal, A. Ozaita, D. Pountney, M. Saganich, E. V. S. de Miera and B. Rudy, Molecular diversity of K+ channels, Ann. N. Y. Acad. Sci. 868 (1999) 233–255.10.1111/j.1749-6632.1999.tb11293.x]Search in Google Scholar
[5. A. D. Goodman, T. R. Brown, L. B. Krupp, R. T. Schapiro, S. R. Schwid, R. Cohen, L. M. Marinucci and A. R. Blight, Sustained-release oral fampridine in multiple sclerosis: a randomised, doubleblind, controlled trial, Lancet373 (2009) 732–738; https://doi.org/10.1016/S0140-6736(09)60442-610.1016/S0140-6736(09)60442-6]Search in Google Scholar
[6. A. D. Goodman, T. R. Brown, K. R. Edwards, L. B. Krupp, R. T. Schapiro, R. Cohen, L. N. Marinucci and A. R. Blight, A phase 3 trial of extended release oral dalfampridine in multiple sclerosis, Ann. Neurol.68 (2010) 494–502; https://doi.org/10.1002/ana.2224010.1002/ana.2224020976768]Search in Google Scholar
[7. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Application Number 22-250s000, Approval Letter, FDA, Silver Spring (MD) 2010; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_Approv.pdf; last access date June 15, 2019]Search in Google Scholar
[8. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), Summary of Opinion (Initial Authorisation) for Fampyra (Fampridine), May 2011; https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fampyra_en.pdf; last access date June 18, 2019]Search in Google Scholar
[9. V. K. Redasani, G. L. Shaikh and S. S. Surana, Development and validation of spectroscopic methods for the estimation of dalfampridine in bulk and in tablet formulation, Anal. Chem. Indian J. 14 (2014) 37–41.]Search in Google Scholar
[10. S. Thomas, S. Shandilya, A. Bharti and A. Agarwal, A stability indicating simultaneous dual wavelength UV-HPLC method for the determination of potential impurities in fampridine active pharmaceutical ingredient, J. Pharm. Biomed. Anal.58 (2012) 136–140; https://doi.org/10.1016/j.jpba.2011.09.00910.1016/j.jpba.2011.09.00922000073]Search in Google Scholar
[11. C. Babu, K. N. Rao, N. Devanna and K. S Reddy, Development and validation of stability indicating reversed phase high performance liquid chromatographic method for the determination of related substances in fampridine drug substance and tablet dosage forms, Asian J. Pharm. Clin. Res. 10 (2017) 334–338.10.22159/ajpcr.2017.v10i10.19796]Search in Google Scholar
[12. N. R. Dharani, K. Padmini and S. Sumakala, Stability indicating RP-HPLC method development and validation for estimation of dalfampridine in its bulk and formulation, Int. J. Adv. Res.4 (2016) 184–191; https://doi.org/10.21474/IJAR01/147110.21474/IJAR01/1471]Search in Google Scholar
[13. M. Jain, V. Srivastava, R. Kumar, V. Dangi, S. G. Hiriyanna, A. Kumar and P. Kumar, Determination of five potential genotoxic impurities in dalfampridine using liquid chromatography, J. Pharm. Biomed. Anal.133 (2017) 27–31; https://doi.org/10.1016/j.jpba.2016.10.013.10.1016/j.jpba.2016.10.01327969064]Search in Google Scholar
[14. W. Smith, S. Swan, T. Marbury and H. Henney, Single-dose pharmacokinetics of sustained-release fampridine (fampridine-SR) in healthy volunteers and adults with renal impairment, J. Clin. Pharmacol. 50 (2010) 151–159; https://doi.org/10.1177/009127000934485710.1177/009127000934485719966074]Search in Google Scholar
[15. A. Suneetha and R. K. Raja, High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study, J. Food. Drug Anal. 24 (2016) 866–875; https://doi.org/10.1016/j.jfda.2016.03.00410.1016/j.jfda.2016.03.00428911626]Search in Google Scholar
[16. A. Suneetha and R. K. Raja, Comparison of LC-UV and LC–MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study, Biomed. Chromatogr.30 (2016) 1371–1377; https://doi.org/10.1002/bmc.369410.1002/bmc.369426849839]Search in Google Scholar
[17. United States Pharmacopeia/National Formulary (USP 42-NF 37), United States Pharmacopeial Convention, Rockville (MD) 2017; last access date November 1, 2019]Search in Google Scholar
[18. A. Dean, D. Voss and D. Draguljic, Design and Analysis of Experiments, 2nd ed., Springer International Publishing, Cham 2017.10.1007/978-3-319-52250-0]Search in Google Scholar
[19. L. Eriksson, E. Johansson, N. Kettaneh-Wold, C. Wilkström and S. Wold, Design of Experiments – Principles and Applications, 3rd ed., MKS Umetrics AB, Umeå 2008.]Search in Google Scholar
[20. A. L. Vonica-Gligor, I. Tomuţă I and S.E. Leucuţa, Piecewise function parameters as responses of the design of experiment in the development of a pulsatile release chronopharmaceutical system, Acta Pharm. 66 (2016) 173–189; https://doi.org/10.1515/acph-2016-002510.1515/acph-2016-002527279062]Search in Google Scholar
[21. A. Ćurić, R. Reul, J. Möschwitzer and G. Fricker, Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments, Int. J. Pharm. 448 (2013) 189–197; https://doi.org/10.1016/j.ijpharm.2013.03.02910.1016/j.ijpharm.2013.03.02923524086]Search in Google Scholar
[22. C. Saroja and P. K. Lakshmi, Formulation and optimization of fenofibrate lipospheres using Taguchi’s experimental design, Acta Pharm. 63 (2013) 71–83; https://doi.org/10.2478/acpb-2013-000810.2478/acpb-2013-000823482314]Search in Google Scholar
[23. B. Sylvester, A. Porfire, D. M. Muntean, L. Vlase and I. Tomuţă, Formulation optimization of pravastatin loaded long-circulating liposomes using a design of experiments, Farmacia64 (2016) 449–458.]Search in Google Scholar
[24. Z. I. Szabó, B. Székely-Szentmiklósi, B. Deák, I. Székely-Szentmiklósi, B. Kovács, K. Zöldi and E. Sipos, Study of the effect of formulation variables on the characteristics of combination tablets containing enalapril maleate and indapamide as active substances using experimental design, Acta Pharm. 66 (2016) 191–206; https://doi.org/10.1515/acph-2016-001910.1515/acph-2016-001927279063]Search in Google Scholar
[25. L. R. Tefas, B. Sylvester, I. Tomuță, A. Sesarman, E. Licarete, M Banciu and A. Porfire, Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach, Drug Des. Devel. Ther. 11 (2017) 1605–1621; https://doi.org/10.2147/DDDT.S12900810.2147/DDDT.S129008544869728579758]Search in Google Scholar
[26. B. Kovács, L. K. Kántor, M. D. Croitoru, É. K. Kelemen, M. Obreja, E. E. Nagy, B. Székely-Szentmiklósi and Á. Gyéresi, Reversed phase HPLC for strontium ranelate: Method development and validation applying experimental design, Acta Pharm.68 (2018) 171–183; https://doi.org/10.2478/acph-2018-001910.2478/acph-2018-001929702478]Search in Google Scholar
[27. P. Shah, T. Pandya, M. Gohel and V. Thakkar, Development and validation of HPLC method for simultaneous estimation of rifampicin and ofloxacin using experimental design, J. Taibah Univ. Sci.13 (2018) 146–154; https://doi.org/10.1080/16583655.2018.154874810.1080/16583655.2018.1548748]Search in Google Scholar
[28. User guide to MODDE Version 12, Sartorius Stedim Data Analytics, Umeå, Sweden, 2017; https://blog.umetrics.com/hubfs/Download%20Files/MODDE%2012.0.1%20User%20Guide.pdf; last access date November 12, 2019]Search in Google Scholar
[29. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Dissolution Methods, FDA, Silver Spring (MD), USA, 2012; https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults.cfm, last access date November 14, 2019]Search in Google Scholar